Results 11 to 20 of about 631 (89)

CAQ Corner: Basic concepts of transplant immunology

, 2022
Liver Transplantation, EarlyView.
Amanda Cheung, Josh Levitsky
wiley   +1 more source

CYP3A5 Gene-Guided Tacrolimus Treatment of Living-Donor Egyptian Kidney Transplanted Patients

Frontiers in Pharmacology, 2020
BackgroundTacrolimus is an approved first-line immunosuppressive agent for kidney transplantations. Part of interindividual and interethnic differences in the response of patients to tacrolimus is attributed to polymorphisms at CYP3A5 metabolic enzyme ...
Effrosyni Mendrinou, Mohamed Elsayed Mashaly, Amir Mohamed Al Okily, Mohamed Elsayed Mohamed, Ayman Fathi Refaie, Essam Mahmoud Elsawy, Hazem Hamed Saleh, Hussein Sheashaa, George P. Patrinos, George P. Patrinos, George P. Patrinos   +10 more
doaj   +1 more source

CYP3A5*3 and SLCO1B1 c.521T>C Polymorphisms Influence the Pharmacokinetics of Atorvastatin and 2-Hydroxy Atorvastatin

Pharmaceutics, 2022
There is a large variability in individual responses to atorvastatin administration. This study assessed the pharmacogenetic effects of solute carrier organic anion transporter family member 1B1 (SLCO1B1, c.388A>G and c.521T>C) and cytochrome P450 3A5 ...
Jin-Woo Park, Jong-Min Kim, Hwa-Young Lee, Jihyeon Noh, Kyoung-Ah Kim, Ji-Young Park   +5 more
doaj   +1 more source

Global pharmacogenomics: distribution of CYP3A5 polymorphisms and phenotypes in the Brazilian population.

PLoS ONE, 2014
The influence of self-reported "race/color", geographical origin and genetic ancestry on the distribution of three functional CYP3A5 polymorphisms, their imputed haplotypes and inferred phenotypes was examined in 909 healthy, adult Brazilians, self ...
Guilherme Suarez-Kurtz, Daniela D Vargens, Ana Beatriz Santoro, Mara H Hutz, Maria Elisabete de Moraes, Sérgio D J Pena, Ândrea Ribeiro-dos-Santos, Marco A Romano-Silva, Claudio José Struchiner   +8 more
doaj   +1 more source

Effect of CYP3A5 Genotypes on the Pharmacokinetics of Carbamazepine when used as Monotherapy or Co-Administered with Phenytoin, Phenobarbital or Valproic Acid in Thai Patients

Journal of Pharmacy & Pharmaceutical Sciences, 2013
Purpose: To determine the effects of CYP3A5 polymorphisms on carbamazepine (CBZ) pharmacokinetic parameters when CBZ is used either as monotherapy or co-administered with phenytoin (PHT), phenobarbital (PB) or valproic acid (VPA).
Duangchit Panomvana, Tharathorn Traiyawong, Somchai Towanabut   +2 more
doaj   +1 more source

Pharmacogenetic and Clinical Predictors of Clopidogrel Insufficiency in a Patient with Atherosclerosis Obliterans of the Lower Extremities: Clinical Case

Рациональная фармакотерапия в кардиологии, 2018
The considered clinical case of combination of multifocal atherosclerotic vascular lesion with type 2 diabetes mellitus and liver fibrosis demonstrates a combination of polyvalent risk factors  for resistance to antiplatelet therapy with clopidogrel. The
M. A. Andreyanova, K. B. Mirzaev, D. A. Sychev, K. A. Ryzhikova, A. V. Pokrovsky, A. F. Kharazov   +5 more
doaj   +1 more source

Effect of polymorphisms in CYP3A4*22 (rs35599367) C>T, CYP3A5*3 (rs776746) A>G, ABCB1 (rs4148738) C>T and ABCB1 (rs1045642) C>T genes on apixaban anticoagulation: pilot study results

Медицинский совет, 2021
Introduction. Apixaban is a direct oral anticoagulant prescribed for treatment and prevention of venous thromboembolism (VTE) and for prevention of stroke in patients with nonvalvular atrial fibrillation.
I. N. Sychev, L. V. Fedina, A. S. Osipov, I. I. Temirbulatov, O. Yu. Tataroy, Zh. A. Sozaeva, K. A. Akmalova, N. P. Denisenko, S. P. Abdullaev, A. A. Kachanova, E. A. Grishina, K. B. Mirzaev, D. A. Sychev   +12 more
doaj   +1 more source

Association of CYP3A4*1B, CYP3A4*22 and CYP3A5*3 polymorphisms carriage with efficacy and safety of tamsulosin in patients with benign prostatic hyperplasia

Фармация и фармакология (Пятигорск)
Tamsulosin is a first-line drug in the treatment of lower urinary tract symptoms (LUTS) in benign prostatic hyperplasia (BPH). Despite high estimates of its efficacy and safety, it rates may vary due to genetic polymorphisms of genes for the enzymes ...
Sh. P. Abdullaev, M. N. Shatokhin, O. L. Sigailo, Sh. P. Abdullaev, P. O. Bochkov, S. N. Tuchkova, O. V. Teodorovich, O. B. Loran, D. A. Sychev   +8 more
doaj   +1 more source

Wuzhi Capsule Dosage Affects Tacrolimus Elimination in Adult Kidney Transplant Recipients, as Determined by a Population Pharmacokinetics Analysis

Pharmacogenomics and Personalized Medicine, 2021
Lizhi Chen,1,* Yunyun Yang,1,2,* Xuebin Wang,1,* Chenyu Wang,2 Weiwei Lin,3 Zheng Jiao,2,4 Zhuo Wang1 1Department of Pharmacy, Shanghai Changhai Hospital, Naval Medical University, Shanghai, 200433, People’s Republic of China; 2Department of ...
Chen L, Yang Y, Wang X, Wang C, Lin W, Jiao Z, Wang Z   +6 more
doaj  

Influence of Genetic Admixture Components on CYP3A5*3 Allele-Associated Hypertension in Amerindian Populations From Northwest Mexico

Frontiers in Pharmacology, 2020
CYP3A5 metabolizes endogenous substrates and ~30% of prescription drugs. The CYP3A5 gene contains an active CYP3A5*1 allele, and a non-functional version, the CYP3A5*3 (rs776746), with consequences for drug therapeutic responses and side effects.
Carlos Galaviz-Hernández, Blanca P. Lazalde-Ramos, Ismael Lares-Assef, Alejo Macías-Salas, Margarita A. Ortega-Chavez, Héctor Rangel-Villalobos, Martha Sosa-Macías   +6 more
doaj   +1 more source